menu search

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...

November 3, 2023, 8:05 pm

Ambrx biopharma: potential with recently released prostate cancer data

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with ...

October 23, 2023, 6:50 pm

Harpoon therapeutics stock soars on ‘promising' lung cancer drug results

Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage immunotherapy company announced that it...

October 23, 2023, 9:32 am

Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg primi...

October 21, 2023, 3:31 pm

Oxford cannabinoid readies for next stage as it safely navigates phase i stduy

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) hailed as a 'major milestone' the successful completion of dosing for all ...

October 10, 2023, 2:22 am

We need to look for hits to specific cohorts not just the consumer broadly: charles schwab's sonders

Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tun...

October 2, 2023, 8:58 pm

Harpoon therapeutics abstract for hpn217 accepted for poster presentation at the 20th international myeloma society annual meeting

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company d...

September 6, 2023, 11:30 am

Nanoviricides reports progress in phase 1a/1b human clinical trial of nv-cov-2 broad-spectrum antiviral drug

NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing succes...

August 21, 2023, 8:16 am

Perspective therapeutics reports second quarter fiscal 2023 results and recent business highlights

Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial ...

August 11, 2023, 12:00 pm

The month in closed-end funds: july 2023

For the second consecutive month, equity CEFs (+2.69% on a NAV basis) on average chalked up plus-side performance while their fixed income CEF ...

August 5, 2023, 3:12 pm

Medicenna: presenting data next week plus a clinical update next quarter

MDNA failed to report data from the fifth dosing cohort, of its phase 1/2 ABILITY study of MDNA11, in Q2'23 as expected. The company is instead presen...

August 1, 2023, 3:49 pm

Replimune: the rise of oncolytic virus therapies in cancer treatment

The company's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Top-line results from ...

July 9, 2023, 1:22 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am


Search within

Pages Search Results: